IL6 and COVID-19: On this basis, a randomized controlled clinical trial to test the clinical efficacy and safety of the administration of IFN‐β1 and IFN‐β2 in moderate‐to‐severe COVID‐19 patients has been designed (NCT04343768) (Figure 2C, Table 1).113